Camrelizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Camrelizumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetPD1
Clinical data
SynonymsSHR-1210
ATC code
  • none
Identifiers
CAS Number

Camrelizumab (SHR-1210) (INN[1]) is a monoclonal antibody that is being investigated for hepatocellular carcinoma.

This drug is being developed by Jiangsu HengRui Medicine Co., Ltd. As of 2018, camrelizumab is undergoing Phase II/III trials.

References[edit]

  1. ^ World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended INN: List 77" (PDF). WHO Drug Information. 31 (1).